European Study of Cerebral Aspergillosis Treated With Isavuconazole
NCT ID: NCT04486885
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2021-08-01
2023-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
NCT00412893
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
NCT04550936
Voriconazole For Chronic Bronchopulmonary Aspergillosis
NCT00159822
Efficacy of Intrabronchial Voriconazole Instillation for Inoperable Pulmonary Aspergilloma
NCT03799809
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis
NCT00002010
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In child or adult
* Treated by isavuconazole at least 7 days
* Diagnosed between March 2017 and June 2020
Exclusion Criteria
* isavuconazole treatment for less than 7 days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imagine Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fanny Lanternier, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Necker
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Necker-Enfants Malades
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
hj-20-ESCAI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.